Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10415264 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL20769827 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL4166195 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL596694 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Octadecylphosphonocholine SCHEMBL744376 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Tetradecylphosphocholine SCHEMBL5481590 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL29465558 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL7189058 | 0.98 | LMNA (0.97) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL9234856 | 0.98 | LMNA (0.96) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934123 | 0.94 | LMNA (0.88) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25537 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117180287-B | Application of miltefosine in promoting bone formation and preventing and treating osteoporosis | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 2026-05-19 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| WO-1996014871-A1 | IMMUNOGENIC COMPOSITIONS | CORTECS LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |
| US-5446033-A | Antitumor agent; storage stability, antiseptic, chemical resistance, by-product inhibition | ASTA MEDICA AG (DE) | 1995-08-29 | — | — | US | claimed |
| WO-1995013795-A1 | HYDROPHOBIC PREPARATIONS | CORTECS LIMITED (GB) | 1995-05-26 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5290769-A | Applying compositions for skin disorders | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-03-01 | — | — | US | claimed |
| EP-0359981-B1 | PHARMACEUTICAL COMBINATIONS AND THEIR USE AS ANTINEOPLASTIC MEDICINES | Roche Diagnostics GmbH (DE) | 1993-07-28 | — | — | EP | claimed |
| US-5049552-A | Anticancer agents | MAX-PLANCK-GESELLSCHAFT FUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1991-09-17 | — | — | US | claimed |
| EP-0248047-B1 | MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1991-06-19 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4837023-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1989-06-06 | — | — | US | claimed |